Trial Profile
Study reporting clinical benefit (objective response + disease stabilization) in clear cell metastatic renal cell carcinoma (cc mRCC) treated with interleukin-2
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 18 Dec 2015 New trial record